Complete your personal information for a more tailored experience
Home
Don't miss out
Subscribe to STAT+ today, for the best life sciences journalism in the industry
By Ed Silverman
Dec. 19, 2024
Pharmalot Columnist, Senior Writer
Most of the formularies run by some of the largest health plans in the U.S. generally provide “fair access” to 11 treatments for several serious diseases, although transparent coverage information is often lacking for some medicines, a new analysis has found.
Almost uniformly, the 11 formularies made the drugs available fairly when judged on three criteria: eligibility based on clinical data, restrictions placed on prescribers, and step therapy, which requires patients to try other medicines before insurers approve a prescription. The formularies are run by health plans, pharmacy benefit managers, and the U.S. Department of Veterans Affairs.
advertisement
But only 81% of the formularies scored well on a fourth criterion: cost-sharing, which is the portion of expenses paid by insured individuals. Although there is a caveat: This particular metric was based on a subset of just three drugs that were deemed to be fairly priced based on a cost-effectiveness assessment — the Mounjaro type 2 diabetes treatment, and the Wegovy and Qsymia obesity drugs.
STAT+ Exclusive Story
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
Totals $468 per year
Starter
$20
for 3 months, then $399/year
Then $399/year
Annual
$399
Save 15%
Save 15%
11+ Users
Custom
Savings start at 25%!
Savings start at 25%!
2-10 Users
$300
Annually per user
$300 Annually per user
To read the rest of this story subscribe to STAT+.
Ed Silverman
Pharmalot Columnist, Senior Writer
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades.
From the lab to the medicine chest, these are the must-read drug industry updates of the day
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
By Ed Silverman
By Ed Silverman
advertisement
By Ed Silverman
By Ed Silverman
By Ed Silverman
By Rachel Cohrs Zhang
By Jason Mast
By Casey Ross and Bob Herman
By Casey Ross
By Adam Feuerstein
Share options
X
Bluesky
LinkedIn
Facebook
Doximity
Copy link
Reprints
Reporting from the frontiers of health and medicine
Company
Account
More
English 
Français